By Adriano Marchese
DexCom shares rose in premarket trading Thursday morning after the company said it received regulatory clearance in the U.S. for its diabetes monitoring system.
Shares traded 8.5% higher at $72.55.
The company, which focuses on glucose biosensing--which measures glucose levels in wearers--said that the Food and Drug Administration has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes.
At 15 and a half days of wear, DexCom said that its system is the longest lasting continuous monitoring system.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 10, 2025 09:13 ET (13:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.